Durvalumab plus gemcitabine and cisplatin is recommended, within its marketing authorisation, as an option for treating locally advanced, unresectable, or metastatic biliary tract cancer in adults. It is only recommended if the company provides durvalumab according to the commercial arrangement.
Limited treatments options are available for unresectable or advanced biliary tract cancer, including cancer which reoccurs after surgery. Standard treatment includes chemotherapy with gemcitabine and cisplatin.
Clinical trial evidence shows that, compared with standard treatment, durvalumab plus gemcitabine and cisplatin increases how long people have before their condition gets worse and how long they live.
The cost-effectiveness estimates are uncertain. When considering the condition's severity, and its effect on quality and length of life, the most likely estimates are within the range that NICE considers an acceptable use of NHS resources. So, durvalumab plus gemcitabine and cisplatin is recommended.